Company record
Sagent Pharmaceuticals, Inc.
1 FDA warning letter since 2023 and 1 recall in the last 12 months.
Get an email the day FDA posts anything new about Sagent Pharmaceuticals, Inc..
Warning letters
-
DrugsSagent Pharmaceuticals, Inc.
FDA found SterRx, acquired by Sagent, made sterile drugs under conditions that risked contamination and lacked sterility assurance.
High risk
Recalls
| Reported | Class | Firm | Product and reason |
|---|---|---|---|
| May 27 | Class III | Sagent Pharmaceuticals Drug |
Busulfan Injection, 60 mg per 10 mL (6 mg per mL), 8x10 mL Single-Dose Vials, Rx only, Mfd. for Sagent Pharmaceuticals, Schaumburg, IL 60195, Made in Canada, NDC 25021-241-10. Failed Impurities/Degradation Specifications |